The price of Envlo is 611 won & Qtern is 833 won per tab

Chong Kun Dang Registers Dapagliflozin + Sitagliptin Before Patent Expiration in September

4 items including Dapagliflozin + Glimepiride are also reimbursed

Zemidapa's price is the highest among SGLT2i+DPP4i combinations

Leading diabetes treatments such as Daewoong Pharmaceutical's new SGLT2i diabetes drug Envlo and AstroGeneca's SGLT2i+DPP4i complex Qtern will be poured out at once in May.

 

In line with the expansion of the Forxiga patent expiration and diabetes drug combined salary standards this month, the application of new product benefits was concentrated in May.

 

According to the industry on the 20th, Daewoong Pharmaceutical's salary will be applied to 611 won per table of 0.3mg per table on the 1st of next month.

 

Envlo is known to have been determined at less than 90% of the price of existing SGLT2i drugs.

 

It is lower than the existing SGLTi treatment Jardiance 10mg 660 won, Sugar 50mg 685 won, and Steglatro 5mg 666 won.

 

The price of Envlo is higher than that of Forxiga, because at the time of calculating the Envlo price, Forxiga was before the patent expired.

 

Forxiga 10mg will be reduced from 734 won to 514 won from May.

 

Hanall Biopharma, an affiliate of Daewoong Pharmaceutical Co., Ltd.

 

with Envlo, Eaglex and Daewoong Bio Benavo's price is the same.

 

The SGLT2i+DPP4i compound will be reimbursed for the first time.

 

Korea's AstraZeneca Qtern 5/10mg, Korea's Beringer Ingelheim's Esglito 10/5mg, Korea's MSD's "Stegluzan 5/100mg" and LG Chem's Zemidapa will be on the list in May.

 

Qtern costs 833 won per tablet, Esglito costs 755 won for 10/5mg, Stgluzan costs 846 won, and Zemidapa costs 940 won per tablet.

 

Chong Kun Dang Exiglu-S will also be on the list in May.

 

It will be four months ahead of the expiration of the Sitagliptin material patent (September 1), drawing keen attention to Chong Kun Dang's strategy.

 

The Dapagliflozin+Sitagliptin combination licensed by domestic companies is expected to be listed after September.

 

These SGLT2i+DPP4i combination are only eligible for benefits in the third system combined with metformin according to the standard.

 

It is on the list for 677 won per tablet, with Hutecs Korea Pharmaceutical's "Gluxiga 10/4mg," Jinyang Pharmaceutical's "Dapagreen-G 10/4mg," Kyungdong Pharmaceutical's "Dapamepi 10/4mg," and Mothers Pharm's Pharmaceutical's "Xig Double M 10/4mg."